Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cambridge Cognition HoldingsLSE:COG 47 3-Year EBITDA Growth Rate is 4.10% as of Dec. 2025, which is at its 10-year median of 4.10. GuruFocus rates LSE:COG with a GF Score™ of 47/100 and a GF Value™ of £0.34 (Fairly Valued). The stock has 5 warning signs investors should review. Among 526 Healthcare Providers & Services companies, Cambridge Cognition Holdings ranks worse than 62.36% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 4.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Cambridge Cognition Holdings was 48.70% per year. The lowest was -64.70% per year. And the median was 4.10% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Cambridge Cognition Holdings 3-Year EBITDA Growth Rate Related Terms
LSE:COG vs VEEV, BTSG, HQY: 3-Year EBITDA Growth Rate Comparison
For the Health Information Services subindustry, Cambridge Cognition Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cambridge Cognition Holdings 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cambridge Cognition Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Cambridge Cognition Holdings's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 4.10% mean?
Cambridge Cognition Holdings (LSE:COG) has a 3-Year EBITDA Growth Rate of 4.10% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Cambridge Cognition Holdings and its competitors. This is near median its historical median of 4.10. According to the industry distribution chart, Cambridge Cognition Holdings ranks #328 out of 526 companies in the Healthcare Providers & Services industry, placing it in the top 62.4%.
Is Cambridge Cognition Holdings' 3-Year EBITDA Growth Rate too high?
Cambridge Cognition Holdings' current 3-Year EBITDA Growth Rate of 4.10% is near median its 10-year median of 4.10. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 10.20. Cambridge Cognition Holdings' value of 4.10% is 59.8% below this industry median. Based on the distribution chart, Cambridge Cognition Holdings ranks #328 out of 526 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Cambridge Cognition Holdings has a GF Score™ of 47/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cambridge Cognition Holdings' 3-Year EBITDA Growth Rate compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Cambridge Cognition Holdings ranks #328 out of 526 companies for 3-Year EBITDA Growth Rate. This places Cambridge Cognition Holdings in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 10.20. Cambridge Cognition Holdings' value of 4.10% is 59.8% below this benchmark. While the company's 10-year median is 4.10 vs. the industry median of 10.20, Cambridge Cognition Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 10.20, based on 526 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cambridge Cognition Holdings's current 3-Year EBITDA Growth Rate of 4.10% is 59.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Cambridge Cognition Holdings and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 10.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cambridge Cognition Holdings's current 3-Year EBITDA Growth Rate is 4.10%, which is near median its own 10-year median of 4.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cambridge Cognition Holdings stock overvalued right now?
Based on GuruFocus' analysis, Cambridge Cognition Holdings (LSE:COG) is currently considered Fairly Valued. The stock's GF Value™ is £0.34, compared to a current price of £0.33 — trading 2.9% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 4.10%, which is near median its 10-year median of 4.10 and 59.8% below the Healthcare Providers & Services industry median of 10.20. Cambridge Cognition Holdings' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Cambridge Cognition Holdings (LSE:COG), the current 3-Year EBITDA Growth Rate is 4.10% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cambridge Cognition Holdings (LSE:COG) Overvalued in 2026?
Based on GuruFocus' analysis, Cambridge Cognition Holdings stock appears to be undervalued.
The current stock price of £0.33 is trading 2.9% below its estimated GF Value™ of £0.34.
GuruFocus considers Cambridge Cognition Holdings to be Fairly Valued.
Key valuation signals for LSE:COG:
3-Year EBITDA Growth Rate: 4.10% (near median its 10-year median of 4.10)
GF Value™: £0.34 vs. price of £0.33 (2.9% below fair value)
Industry Position: 59.8% below the Healthcare Providers & Services median (#328 of 526)
No single metric tells the full story. See the LSE:COG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cambridge Cognition Holdings PLC is a neuroscience digital health company specializing in the measurement of clinical outcomes in neurological disorders. It develops and commercialises neuroscience technologies to assess cognitive function for sale across the world. The company's products include CANTAB web-based assessments, Electronic questionnaires and scales (eCOA), NeuroVocalix Winterlight, a voice analysis tool to assess cognitive changes, high-frequency testing kits, and Clinpal, among others. Its operating segments are: Clinical studies, which generate maximum revenue, Academic research, Professional Healthcare, and Consumer Health & Wellness. Geographically, the company generates maximum revenue from the USA, and the rest from the UK, the European Union, and the Rest of the world.
47GF Score
Get the complete analysis for LSE:COG
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:COG has been successfully added to your 
